IDH mutation vs. IDH wild-type confers superior prognosis, particularly when accompanied by 1p19q co-deletion altering the management of non-GBM gliomas in terms of type and timing of systemic management, while GBMs are treated with standard-of-care concurrent chemo-irradiation irrespective of IDH status. This evidence concerns the gene IDH2 and glioma.